$2.61 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 93 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FIXX | HOMOLOGY MEDICINES INC | $144,946,000 | +24.0% | 5,227,035 | 0.0% | 5.56% | +18.8% | |
| ORTX | ORCHARD THERAPEUTICS PLCads | $143,462,000 | +13.7% | 8,023,600 | 0.0% | 5.50% | +8.9% | |
| NEVRO CORPnote 1.750% 6/0 | $100,936,000 | +9.4% | 100,000,000 | 0.0% | 3.87% | +4.8% | ||
| INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $57,201,000 | +7.9% | 57,791,000 | 0.0% | 2.19% | +3.3% | ||
| ANAB | ANAPTYSBIO INC | $54,308,000 | +14.5% | 743,439 | 0.0% | 2.08% | +9.7% | |
| MYOK | MYOKARDIA INC | $51,834,000 | +6.4% | 997,000 | 0.0% | 1.99% | +1.9% | |
| ACRS | ACLARIS THERAPEUTICS INC | $35,302,000 | -18.9% | 5,893,416 | 0.0% | 1.35% | -22.3% | |
| RARX | RA PHARMACEUTICALS INC | $33,645,000 | +23.1% | 1,502,000 | 0.0% | 1.29% | +17.9% | |
| RETA | REATA PHARMACEUTICALS INCcl a | $31,111,000 | +52.4% | 364,000 | 0.0% | 1.19% | +46.0% | |
| KEMPHARM INCnote 5.500% 2/0 | $28,677,000 | -27.1% | 65,423,000 | 0.0% | 1.10% | -30.2% | ||
| EDIT | EDITAS MEDICINE INC | $28,334,000 | +7.5% | 1,158,841 | 0.0% | 1.09% | +3.0% | |
| DFBHU | DFB HEALTHCARE ACQUISTION COunit 01/30/2023 | $25,375,000 | +0.5% | 2,500,000 | 0.0% | 0.97% | -3.8% | |
| EXACT SCIENCES CORPdbcv 1.000% 1/1 | $20,483,000 | +24.1% | 15,000,000 | 0.0% | 0.78% | +18.9% | ||
| BOLD | AUDENTES THERAPEUTICS INC | $19,272,000 | +83.0% | 493,901 | 0.0% | 0.74% | +75.1% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $18,603,000 | +44.9% | 650,000 | 0.0% | 0.71% | +38.7% | |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $14,103,000 | +10.6% | 607,633 | 0.0% | 0.54% | +5.9% | |
| MOR | MORPHOSYS AGsponsored ads | $13,632,000 | -10.2% | 600,000 | 0.0% | 0.52% | -14.0% | |
| ARVN | ARVINAS INC | $13,597,000 | +14.9% | 921,234 | 0.0% | 0.52% | +9.9% | |
| SYRS | SYROS PHARMACEUTICALS INC | $11,598,000 | +64.1% | 1,268,945 | 0.0% | 0.44% | +57.2% | |
| ALLO | ALLOGENE THERAPEUTICS INC | $9,448,000 | +7.4% | 326,797 | 0.0% | 0.36% | +2.8% | |
| SYBX | SYNLOGIC INC | $8,407,000 | +8.3% | 1,107,643 | 0.0% | 0.32% | +3.5% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $7,976,000 | +2.0% | 291,005 | 0.0% | 0.31% | -2.2% | |
| NUVASIVE INCnote 2.250% 3/1 | $7,782,000 | +5.8% | 7,000,000 | 0.0% | 0.30% | +1.4% | ||
| TELIGENT INC NEWnote 4.750% 5/0 | $6,453,000 | -1.3% | 9,567,000 | 0.0% | 0.25% | -5.7% | ||
| ALIM | ALIMERA SCIENCES INC | $6,416,000 | +47.6% | 6,052,935 | 0.0% | 0.25% | +41.4% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $4,911,000 | +18.3% | 280,000 | 0.0% | 0.19% | +13.3% | |
| MGTX | MEIRAGTX HOLDINGS PLC | $4,032,000 | +78.7% | 234,000 | 0.0% | 0.16% | +72.2% | |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $3,920,000 | -44.2% | 2,722,241 | 0.0% | 0.15% | -46.6% | |
| AACH | AAC HLDGS INC | $3,562,000 | +31.4% | 1,936,027 | 0.0% | 0.14% | +26.9% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $3,262,000 | +86.4% | 475,450 | 0.0% | 0.12% | +78.6% | |
| STIM | NEURONETICS INC | $2,425,000 | -21.2% | 159,000 | 0.0% | 0.09% | -24.4% | |
| SVRA | SAVARA INC | $1,843,000 | -2.6% | 250,000 | 0.0% | 0.07% | -6.6% | |
| EYEN | EYENOVIA INC | $1,797,000 | +110.2% | 300,000 | 0.0% | 0.07% | +102.9% | |
| PRTO | PROTEON THERAPEUTICS INC | $616,000 | -77.8% | 1,224,899 | 0.0% | 0.02% | -78.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.